Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer

PHASE4RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

February 26, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Endometrial Cancer
Interventions
DRUG

NEPA (300mg netupitant/0.5mg palonosetron)

a single dose (capsule) of NEPA (300mg netupitant/0.5 palonosetron) at day 1 for a maximum of 4 cycles

Trial Locations (8)

10128

ACTIVE_NOT_RECRUITING

Azienda Ospedaliera Ordine Mauriziano di Torino, Torino

20126

NOT_YET_RECRUITING

AOU Città della Salute e della Scienza di Torino, Torino

20133

RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

20141

ACTIVE_NOT_RECRUITING

Istituto Europeo di Oncologia, Milan

23900

RECRUITING

ASST Lecco - A. Manzoni Hospital, Lecco

25123

NOT_YET_RECRUITING

ASST Spedali Civili di Brescia, Brescia

33081

NOT_YET_RECRUITING

Centro di Riferimento Oncologico (CRO) IRCCS, Aviano

35128

RECRUITING

Istituto Oncologico Veneto, Padua

All Listed Sponsors
lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER